Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 3/20 | 0.57 |
| ▸ | ANPEP | P15144 | 1/20 | 0.53 |
| ▸ | IL1RN | P18510 | 1/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.53 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30506402 | 0.94 | LTA4H (0.58) | GHSRANPEPERAP2ERAP1LNPEP | |
| SCHEMBL30958546 | 0.94 | LTA4H (0.58) | GHSRANPEPERAP2ERAP1LNPEP | |
| SCHEMBL31171028 | 0.93 | GHSR (0.58) | GHSRANPEPIL1RNERAP2ERAP1 | |
| SCHEMBL29577979 | 0.91 | LTA4H (0.57) | GHSRANPEPERAP2ERAP1 | |
| SCHEMBL29577130 | 0.91 | LTA4H (0.57) | GHSRANPEPERAP2ERAP1 | |
| SCHEMBL31171024 | 0.91 | OPRM1 (0.54) | GHSR | |
| SCHEMBL30671563 | 0.90 | LTA4H (0.58) | GHSRANPEPERAP2ERAP1 | |
| SCHEMBL30799643 | 0.90 | GHSR (0.48) | GHSR | |
| SCHEMBL30490004 | 0.90 | OPRM1 (0.54) | GHSR | |
| SCHEMBL31259936 | 0.89 | ACE (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | GHSR 1194/4885ANPEP 100/4885IL1RN 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.